An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression
Open Access
- 1 September 2012
- journal article
- Published by Oxford University Press (OUP) in International Journal of Neuropsychopharmacology
- Vol. 15 (8), 1063-1072
- https://doi.org/10.1017/s1461145711001593
Abstract
Amino-acid neurotransmitter system dysfunction plays a major role in the pathophysiology of major depressive disorder (MDD). We used proton magnetic resonance spectroscopy (1H-MRS) to investigate whether prefrontal levels of amino-acid neurotransmitters predict antidepressant response to a single intravenous infusion of the N-methyl-d-aspartate (NMDA) antagonist ketamine in MDD patients. Fourteen drug-free patients with MDD were scanned 1–3 d before receiving a single intravenous infusion of ketamine (0.5 mg/kg). We measured gamma aminobutyric acid (GABA), glutamate, and Glx/glutamate ratio (a surrogate marker of glutamine) in the ventromedial prefrontal cortex (VM-PFC) and the dorsomedial/dorsal anterolateral prefrontal cortex (DM/DA-PFC). Correlation analyses were conducted to determine whether pretreatment GABA, glutamate, or Glx/glutamate ratio predicted change in depressive and anxiety symptoms 230 min after ketamine administration. Pretreatment GABA or glutamate did not correlate with improved depressive symptoms in either of the two regions of interest (p>0.1); pretreatment Glx/glutamate ratio in the DM/DA-PFC was negatively correlated with improvement in depressive symptoms [rs(11)=−0.57, p<0.05]. Pretreatment glutamate levels in the VM-PFC were positively correlated with improvement in anxiety symptoms [rs(11)=0.57, p<0.05]. The findings suggest an association between lower Glx/glutamate ratio and greater improvement in response to ketamine treatment. Because glutamine is mainly contained in glia, the decreased Glx/glutamate ratio observed in this study may reflect the reduction in glial cells found in the same regions in post-mortem studies of individuals with MDD, and suggests that the presence of this neuropathological construct may be associated with antidepressant responsiveness to ketamine.Keywords
This publication has 41 references indexed in Scilit:
- Signaling pathways underlying the rapid antidepressant actions of ketamineNeuropharmacology, 2012
- NMDA receptor blockade at rest triggers rapid behavioural antidepressant responsesNature, 2011
- Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depressionMolecular Psychiatry, 2010
- The Relationship Between Aberrant Neuronal Activation in the Pregenual Anterior Cingulate, Altered Glutamatergic Metabolism, and Anhedonia in Major DepressionArchives of General Psychiatry, 2009
- An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment-Refractory Major Depressive DisorderJournal of Clinical Psychopharmacology, 2008
- Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant TreatmentCNS & Neurological Disorders - Drug Targets, 2007
- Gliogenesis and Glial Pathology in DepressionCNS & Neurological Disorders - Drug Targets, 2007
- Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depressionProceedings of the National Academy of Sciences of the United States of America, 2005
- Does glutamate image your thoughts?Trends in Neurosciences, 2002
- Glutamine synthetase immunoreactivity is present in oligodendroglia of various regions of the central nervous systemGlia, 1990